Rational, computer-enabled peptide drug design: principles, methods, applications and future directions

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20(1), 122–128 (2015).Crossref, Medline, CAS, Google Scholar
• 2 Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov. Today 18(17–18), 807–817 (2013).Crossref, Medline, CAS, Google Scholar
• 3 Bashiruddin NK, Suga H. Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies. Curr. Opin. Chem. Biol. 24, 131–138 (2015).Crossref, Medline, CAS, Google Scholar
• 4 Lian W, Upadhyaya P, Rhodes CA, Liu Y, Pei D. Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-alpha antagonist. J. Am. Chem. Soc. 135(32), 11990–11995 (2013).Crossref, Medline, CAS, Google Scholar
• 5 Hu Y, Bajorath J. High-resolution view of compound promiscuity. F1000 Research 2, 144 (2013).Crossref, Medline, Google Scholar
• 6 Nicolaou CA, Brown N. Multi-objective optimization methods in drug design. Drug Discov. Today Technol. 10(3), e427–e435 (2013).Crossref, Medline, Google Scholar
• 7 Frank AO, Vangamudi B, Feldkamp MD et al. Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. J. Med. Chem. 57(6), 2455–2461 (2014).Crossref, Medline, CAS, Google Scholar
• 8 Koolpe M, Burgess R, Dail M, Pasquale EB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 280(17), 17301–17311 (2005).Crossref, Medline, CAS, Google Scholar
• 9 Hosseini M, Jiang L, Sorensen HP et al. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. Mol. Pharmacol. 80(4), 585–597 (2011).Crossref, Medline, CAS, Google Scholar
• 10 Kim D, Lee IH, Kim S et al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res. 74(8), 2144–2151 (2014).Crossref, Medline, CAS, Google Scholar
• 11 London N, Gulla S, Keating AE, Schueler-Furman O. In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2. Biochemistry 51(29), 5841–5850 (2012).Crossref, Medline, CAS, Google Scholar
• 12 Chen Z, Hu Y, Hong J et al. Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel. Sci. Rep. 5, 9881 (2015).Crossref, Medline, CAS, Google Scholar
• 13 Quartararo JS, Wu P, Kritzer JA. Peptide bicycles that inhibit the Grb2 SH2 domain. ChemBioChem 13(10), 1490–1496 (2012).Crossref, Medline, CAS, Google Scholar
• 14 Williams BA, Diehnelt CW, Belcher P et al. Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. J. Am. Chem. Soc. 131(47), 17233–17241 (2009).Crossref, Medline, CAS, Google Scholar
• 15 Diehnelt CW, Shah M, Gupta N et al. Discovery of high-affinity protein binding ligands--backwards. PLoS ONE 5(5), e10728 (2010).Crossref, Medline, Google Scholar
• 16 Brauer F, Schmidt K, Zahn RC et al. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob. Agents Chemother. 57(2), 679–688 (2013).Crossref, Medline, CAS, Google Scholar
• 17 Bennett CL, Jacob S, Hymes J, Usvyat LA, Maddux FW. Anaphylaxis and hypotension after administration of peginesatide. N. Engl. J. Med. 370(21), 2055–2056 (2014).Crossref, Medline, Google Scholar
• 18 Weinstock MT, Francis JN, Redman JS, Kay MS. Protease-resistant peptide design-empowering nature's fragile warriors against HIV. Biopolymers 98(5), 431–442 (2012).Crossref, Medline, CAS, Google Scholar
• 19 Baeriswyl V, Heinis C. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. Protein Eng. Des. Sel. 26(1), 81–89 (2013).Crossref, Medline, CAS, Google Scholar
• 20 Galati R, Verdina A, Falasca G, Chersi A. Increased resistance of peptides to serum proteases by modification of their amino groups. Z. Naturforsch. 58(7–8), 558–561 (2003).Crossref, Medline, CAS, Google Scholar
• 21 Nguyen LT, Chau JK, Perry NA, De Boer L, Zaat SA, Vogel HJ. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS ONE 5(9), (2010).Crossref, Google Scholar
• 22 Heard KR, Wu W, Li Y et al. A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. J. Med. Chem. 56(21), 8339–8351 (2013).Crossref, Medline, CAS, Google Scholar
• 23 Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem. 57(15), 6275–6288 (2014).Crossref, Medline, CAS, Google Scholar
• 24 Howell SM, Fiacco SV, Takahashi TT et al. Serum stable natural peptides designed by mRNA display. Sci. Rep. 4, 6008 (2014).•• Shows how the rational use of phage display and natural amino acids can be used to optimize the proteolytic and serum stability of peptides without compromising potency.Crossref, Medline, CAS, Google Scholar
• 25 Sharma S, Singh R, Rana S. Bioactive peptides: a review. Int. J. Bioautomation 15(4), 223–250 (2011).CAS, Google Scholar
• 26 Tsomaia N. Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem. 94, 459–470 (2015).Crossref, Medline, CAS, Google Scholar
• 27 Ano R, Kimura Y, Shima M, Matsuno R, Ueno T, Akamatsu M. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 12(1), 257–264 (2004).Crossref, Medline, CAS, Google Scholar
• 28 Rezai T, Bock JE, Zhou MV, Kalyanaraman C, Lokey RS, Jacobson MP. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128(43), 14073–14080 (2006).Crossref, Medline, CAS, Google Scholar
• 29 Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128(8), 2510–2511 (2006).Crossref, Medline, CAS, Google Scholar
• 30 White TR, Renzelman CM, Rand AC et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol. 7(11), 810–817 (2011).Crossref, Medline, CAS, Google Scholar
• 31 Rafi SB, Hearn BR, Vedantham P, Jacobson MP, Renslo AR. Predicting and improving the membrane permeability of peptidic small molecules. J. Med. Chem. 55(7), 3163–3169 (2012).Crossref, Medline, CAS, Google Scholar
• 32 Rand AC, Leung SS, Eng H et al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance. MedChemComm 3(10), 1282–1289 (2012).Crossref, Medline, CAS, Google Scholar
• 33 Bockus AT, Lexa KW, Pye CR et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. 58(11), 4581–4589 (2015).Crossref, Medline, CAS, Google Scholar
• 34 Hewitt WM, Leung SS, Pye CR et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137(2), 715–721 (2015).Crossref, Medline, CAS, Google Scholar
• 35 Wang CK, Northfield SE, Swedberg JE et al. Exploring experimental and computational markers of cyclic peptides: charting islands of permeability. Eur. J. Med. Chem. 97, 202–213 (2015).Crossref, Medline, CAS, Google Scholar
• 36 Kwon YU, Kodadek T. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. Chem. Biol. 14(6), 671–677 (2007).Crossref, Medline, CAS, Google Scholar
• 37 Mikol V, Kallen J, Pflugl G, Walkinshaw MD. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J. Mol. Biol. 234(4), 1119–1130 (1993).Crossref, Medline, CAS, Google Scholar
• 38 Hughes JD, Blagg J, Price DA et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18(17), 4872–4875 (2008).Crossref, Medline, CAS, Google Scholar
• 39 Altschuh D, Vix O, Rees B, Thierry JC. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. Science 256(5053), 92–94 (1992).Crossref, Medline, CAS, Google Scholar
• 40 Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031–1035 (2010).•• Shows that a small peptide motif can be used to transport a small molecule, another peptide or an antibody into cancer cells via the neuropillin pathway. This demonstrates the potential for peptides to be engineered to exploit cellular transport mechanisms to solve ADME problems.Crossref, Medline, CAS, Google Scholar
• 41 Roth L, Agemy L, Kotamraju VR et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 31(33), 3754–3763 (2012).Crossref, Medline, CAS, Google Scholar
• 42 Alberici L, Roth L, Sugahara KN et al. De novo design of a tumor-penetrating peptide. Cancer Res. 73(2), 804–812 (2013).Crossref, Medline, CAS, Google Scholar
• 43 Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides. Front. Oncol. 3, 216 (2013).Crossref, Medline, Google Scholar
• 44 Pang HB, Braun GB, Friman T et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun. 5, 4904 (2014).Crossref, Medline, CAS, Google Scholar
• 45 Sugahara KN, Braun GB, De Mendoza TH et al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol. Cancer Ther. 14(1), 120–128 (2015).Crossref, Medline, CAS, Google Scholar
• 46 Lu J, Cheng Y, Zhang G et al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Mol. Med. Rep. 12(2), 2668–2676 (2015).Crossref, Medline, CAS, Google Scholar
• 47 Barr MP, Gray SG, Gately K et al. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Mol. Cancer 14(1), 45 (2015).Crossref, Medline, Google Scholar
• 48 Jiang H, Xi Q, Wang F, Sun Z, Huang Z, Qi L. Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. Mol. Med. Rep. 12(2), 2114–2120 (2015).Crossref, Medline, CAS, Google Scholar
• 49 Chaudhary B, Elkord E. Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opin. Ther. Targets 19(2), 147–161 (2015).Crossref, Medline, CAS, Google Scholar
• 50 Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J. Membrane Biol. 247(4), 291–307 (2014).Crossref, Medline, CAS, Google Scholar
• 51 Fang L, Wang M, Gou S, Liu X, Zhang H, Cao F. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs. J. Med. Chem. 57(3), 1116–1120 (2014).Crossref, Medline, CAS, Google Scholar
• 52 Han X, Sun J, Wang Y, He Z. PepT1, ASBT-linked prodrug strategy to improve oral bioavailability and tissue targeting distribution. Curr. Drug Metabol. 16(1), 71–83 (2015).Crossref, Medline, Google Scholar
• 53 Jin SE, Jin HE, Hong SS. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics. Expert Opin. Ther. Targets doi:10.1517/14728222.2015.1044975 (2015) (Epub ahead of print).Crossref, Medline, Google Scholar
• 54 Kapoor P, Singh H, Gautam A, Chaudhary K, Kumar R, Raghava GP. TumorHoPe: a database of tumor homing peptides. PLoS ONE 7(4), e35187 (2012).Crossref, Medline, CAS, Google Scholar
• 55 Fazen CH, Valentin D, Fairchild TJ, Doyle RP. Oral delivery of the appetite suppressing peptide hPYY(3–36) through the vitamin B12 uptake pathway. J. Med. Chem. 54(24), 8707–8711 (2011).Crossref, Medline, CAS, Google Scholar
• 56 Clardy-James S, Chepurny OG, Leech CA, Holz GG, Doyle RP. Synthesis, characterization and pharmacodynamics of vitamin-B12-conjugated glucagon-like peptide-1. ChemMedChem 8(4), 582–586 (2013).Crossref, Medline, CAS, Google Scholar
• 57 Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol. 20(1), 77–95 (2000).Crossref, Medline, CAS, Google Scholar
• 58 Staquicini FI, Ozawa MG, Moya CA et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121(1), 161 (2011).Crossref, Medline, CAS, Google Scholar
• 59 Demeule M, Regina A, Che C et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324(3), 1064–1072 (2008).Crossref, Medline, CAS, Google Scholar
• 60 Demeule M, Beaudet N, Régina A et al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J. Clin. Invest. 124(3), 1199 (2014).Crossref, Medline, CAS, Google Scholar
• 61 Regina A, Demeule M, Che C et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155(2), 185–197 (2008).Crossref, Medline, CAS, Google Scholar
• 62 Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39–43 (2007).Crossref, Medline, CAS, Google Scholar
• 63 Liu Y, Guo Y, An S et al. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PLoS ONE 8(5), e62905 (2013).Crossref, Medline, CAS, Google Scholar
• 64 Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341–345 (2011).Crossref, Medline, CAS, Google Scholar
• 65 Chen W, Zhan C, Gu B et al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J. Drug Target. 19(3), 228–234 (2011).Crossref, Medline, CAS, Google Scholar
• 66 Van Dorpe S, Bronselaer A, Nielandt J et al. Brainpeps: the blood-brain barrier peptide database. Brain Struct. Funct. 217(3), 687–718 (2012).Crossref, Medline, Google Scholar
• 67 Hughes FM Jr, Shaner BE, Brower JO, Woods RJ, Dix TA. Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain. Open Med. Chem. J. 7, 16–22 (2013).Crossref, Medline, CAS, Google Scholar
• 68 Bockus AT, Lexa KW, Pye CR et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. 58(11), 4581–4589 (2015).Crossref, Medline, CAS, Google Scholar
• 69 Nielsen DS, Hoang HN, Lohman RJ et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. Engl. 53(45), 12059–12063 (2014).Crossref, Medline, CAS, Google Scholar
• 70 Ogawa T, Miyamae T, Murayama K et al. Synthesis and structure-activity relationships of an orally available and long-acting analgesic peptide, N(alpha)-amidino-Tyr-D-Arg-Phe-MebetaAla-OH (ADAMB). J. Med. Chem. 45(23), 5081–5089 (2002).Crossref, Medline, CAS, Google Scholar
• 71 Hess S, Linde Y, Ovadia O et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J. Med. Chem. 51(4), 1026–1034 (2008).Crossref, Medline, CAS, Google Scholar
• 72 Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet. 30(2), 141–179 (1996).Crossref, Medline, CAS, Google Scholar
• 73 Kuroda D, Shirai H, Jacobson MP, Nakamura H. Computer-aided antibody design. Protein Eng. Des. Sel. 25(10), 507–521 (2012).Crossref, Medline, CAS, Google Scholar
• 74 Rentzsch R, Renard BY. Docking small peptides remains a great challenge: an assessment using AutoDock Vina. Brief Bioinform. doi:10.1093/bib/bbv008 (2015) (Epub ahead of print).Crossref, Medline, Google Scholar
• 75 Pike DH, Nanda V. Empirical estimation of local dielectric constants: toward atomistic design of collagen mimetic peptides. Biopolymers 104(4), 360–370 (2015).Crossref, Medline, CAS, Google Scholar
• 76 Audie J, Swanson J. Recent work in the development and application of protein-peptide docking. Future Med. Chem. 4(12), 1619–1644 (2012).Link, CAS, Google Scholar
• 77 Das R. Four small puzzles that Rosetta doesn't solve. PLoS ONE 6(5), e20044 (2011).Crossref, Medline, CAS, Google Scholar
• 78 TumorHoPe – Tumor Homing Peptide Database. http://crdd.osdd.net/raghava/tumorhope.Google Scholar
• 79 Volpe DA. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem. 3(16), 2063–2077 (2011).Link, CAS, Google Scholar
• 80 Brainpeps. http://brainpeps.ugent.be.Google Scholar
• 81 Hansen MR, Villar HO, Feyfant E. Development of an informatics platform for therapeutic protein and peptide analytics. J. Chem. Inform. Model. 53(10), 2774–2779 (2013).Crossref, Medline, CAS, Google Scholar
• 82 Altoris - SARvision. www.chemapps.com/sarvision-biologics.Google Scholar
• 83 Thevenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tuffery P. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 40, W288–W293 (2012).•• Describes the use of PEP-fold to predict peptide structures. Suggests that computational methods can be used to accurately model peptide structures and that future improvements will crucially depend on improvements in scoring.Crossref, Medline, CAS, Google Scholar
• 84 PEP-FOLD Server. http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD.Google Scholar
• 85 Vanhee P, Reumers J, Stricher F et al. PepX: a structural database of non-redundant protein-peptide complexes. Nucleic Acids Res. 38, D545–D551 (2010).Crossref, Medline, CAS, Google Scholar
• 86 PepX. www.switchlab.org/bioinformatics/pepx.Google Scholar
• 87 Das AA, Sharma OP, Kumar MS, Krishna R, Mathur PP. PepBind: a comprehensive database and computational tool for analysis of protein-peptide interactions. Genomics Proteomics Bioinform. 11(4), 241–246 (2013).Crossref, Medline, Google Scholar
• 88 PepBind. http://pepbind.bicpu.edu.in.Google Scholar
• 89 London N, Movshovitz-Attias D, Schueler-Furman O. The structural basis of peptide-protein binding strategies. Structure 18(2), 188–199 (2010).Crossref, Medline, CAS, Google Scholar
• 90 London N, Raveh B, Cohen E, Fathi G, Schueler-Furman O. Rosetta FlexPepDock web server--high resolution modeling of peptide-protein interactions. Nucleic Acids Res. 39, W249–W253 (2011).Crossref, Medline, CAS, Google Scholar
• 91 FlexPepDock. http://flexpepdock.furmanlab.cs.huji.ac.il.Google Scholar
• 92 Raveh B, London N, Zimmerman L, Schueler-Furman O. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS ONE 6(4), e18934 (2011).Crossref, Medline, CAS, Google Scholar
• 93 Li H, Lu L, Chen R, Quan L, Xia X, Lu Q. PaFlexPepDock: parallel ab-initio docking of peptides onto their receptors with full flexibility based on Rosetta. PLoS ONE 9(5), e94769 (2014).Crossref, Medline, Google Scholar
• 94 Ben-Shimon A, Niv MY. AnchorDock: blind and flexible anchor-driven peptide docking. Structure 23(5), 929–940 (2015).Crossref, Medline, CAS, Google Scholar
• 95 Trellet M, Melquiond AS, Bonvin AM. A unified conformational selection and induced fit approach to protein-peptide docking. PLoS ONE 8(3), e58769 (2013).• Provides a good discussion of many aspects of docking peptides that need to be considered to obtain accurate results.Crossref, Medline, CAS, Google Scholar
• 96 HADDOCK. http://haddocking.org.Google Scholar
• 97 Kurcinski M, Jamroz M, Blaszczyk M, Kolinski A, Kmiecik S. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. Nucleic Acids Res. 43(W1), W419–W424 (2015).Crossref, Medline, CAS, Google Scholar
• 98 CABS-Dock. http://biocomp.chem.uw.edu.pl/CABSdock.Google Scholar
• 99 Lee H, Heo L, Lee MS, Seok C. GalaxyPepDock: a protein-peptide docking tool based on interaction similarity and energy optimization. Nucleic Acids Res. 43(W1), W431–W435 (2015).Crossref, Medline, CAS, Google Scholar
• 100 GalaxyPepDock. http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=PEPDOCK.Google Scholar
• 101 Yan C, Zou X. Predicting peptide binding sites on protein surfaces by clustering chemical interactions. J. Comput. Chem. 36(1), 49–61 (2015).Crossref, Medline, CAS, Google Scholar
• 102 Verschueren E, Vanhee P, Rousseau F, Schymkowitz J, Serrano L. Protein-peptide complex prediction through fragment interaction patterns. Structure 21(5), 789–797 (2013).Crossref, Medline, CAS, Google Scholar
• 103 Saladin A, Rey J, Thevenet P, Zacharias M, Moroy G, Tuffery P. PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces. Nucleic Acids Res. 42, W221–W226 (2014).Crossref, Medline, CAS, Google Scholar
• 104 PEP-Site Finder. http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-SiteFinder.Google Scholar
• 105 Unal EB, Gursoy A, Erman B. VitAL: Viterbi algorithm for de novo peptide design. PLoS ONE 5(6), e10926 (2010).Crossref, Medline, Google Scholar
• 106 Bhattacherjee A, Wallin S. Exploring protein-peptide binding specificity through computational peptide screening. PLoS Comput. Biol. 9(10), e1003277 (2013).Crossref, Medline, Google Scholar
• 107 Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J. Med. Chem. 54(19), 6492–6500 (2011).Crossref, Medline, CAS, Google Scholar
• 108 Du QS, Huang RB, Chou KC. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Peptide Sci. 9(3), 248–260 (2008).Crossref, Medline, CAS, Google Scholar
• 109 Du QS, Ma Y, Xie NZ, Huang RB. Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions. SAR QSAR Environ. Res. 25(10), 837–851 (2014).Crossref, Medline, CAS, Google Scholar
• 110 Du QS, Wei YT, Pang ZW, Chou KC, Huang RB. Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction. Protein Eng. Des. Sel. 20(9), 417–423 (2007).Crossref, Medline, CAS, Google Scholar
• 111 Du QS, Xie NZ, Huang RB. Recent development of Peptide drugs and advance on theory and methodology of Peptide inhibitor design. Med. Chem. 11(3), 235–247 (2015).Crossref, Medline, CAS, Google Scholar
• 112 Bhonsle JB, Clark T, Bartolotti L, Hicks RP. A brief overview of antimicrobial peptides containing unnatural amino acids and ligand-based approaches for peptide ligands. Curr. Top. Med. Chem. 13(24), 3205–3224 (2013).Crossref, Medline, CAS, Google Scholar
• 113 Giguere S, Laviolette F, Marchand M et al. Machine learning assisted design of highly active peptides for drug discovery. PLoS Comput. Biol. 11(4), e1004074 (2015).Crossref, Medline, Google Scholar
• 114 Beaufays J, Lins L, Thomas A, Brasseur R. In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues. J. Peptide Sci. 18(1), 17–24 (2012).Crossref, Medline, CAS, Google Scholar
• 115 Klepeis JL, Lindorff-Larsen K, Dror RO, Shaw DE. Long-timescale molecular dynamics simulations of protein structure and function. Curr. Opin. Struct. Biol. 19(2), 120–127 (2009).Crossref, Medline, CAS, Google Scholar
• 116 Lindorff-Larsen K, Piana S, Dror RO, Shaw DE. How fast-folding proteins fold. Science 334(6055), 517–520 (2011).Crossref, Medline, CAS, Google Scholar
• 117 Denisiuk A, Schubert V, Wolter FE, Irran E, Trouillas P, Sussmuth RD. Conformational investigation of antibiotic proximicin by X-ray structure analysis and quantum studies suggest a stretched conformation of this type of gamma-peptide. Bioorg. Med. Chem. 21(12), 3582–3589 (2013).Crossref, Medline, CAS, Google Scholar
• 118 Han C, Wang J. Influence of an unnatural amino acid side chain on the conformational dynamics of peptides. ChemPhysChem 13(6), 1522–1534 (2012).Crossref, Medline, CAS, Google Scholar
• 119 Improta R, Vitagliano L, Esposito L. Bond distances in polypeptide backbones depend on the local conformation. Acta Crystallogr. D Biol. Crystallogr. 71(Pt 6), 1272–1283 (2015).Crossref, Medline, CAS, Google Scholar
• 120 Haslach EM, Huang H, Dirain M et al. Identification of tetrapeptides from a mixture based positional scanning library that can restore nM full agonist function of the L106P, I69T, I102S, A219V, C271Y, and C271R human melanocortin-4 polymorphic receptors (hMC4Rs). J. Med. Chem. 57(11), 4615–4628 (2014).Crossref, Medline, CAS, Google Scholar
• 121 Walshe VA, Hattotuwagama CK, Doytchinova IA, Flower DR. A dataset of experimental HLA-B*2705 peptide binding affinities. Dataset Papers in Science 2014, 4 (2014).Crossref, Google Scholar
• 122 Fransson R, Skold C, Kratz JM et al. Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1–7 binding site and with improved metabolic stability and cell permeability. J. Med. Chem. 56(12), 4953–4965 (2013).Crossref, Medline, CAS, Google Scholar
• 123 Tal-Gan Y, Hurevich M, Klein S et al. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J. Med. Chem. 54(14), 5154–5164 (2011).Crossref, Medline, CAS, Google Scholar
• 124 Phan J, Li Z, Kasprzak A et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 285(3), 2174–2183 (2010).•• Describes the rational integration of phage display, biophysical experiments and structure-based design to successfully develop a peptide with dual inhibitor activities.Crossref, Medline, CAS, Google Scholar
• 125 Smadbeck J, Peterson MB, Zee BM et al. De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS ONE 9(4), e95535 (2014).Crossref, Medline, Google Scholar
• 126 Feng S, Zou L, Ni Q et al. Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor. Cell Biochem. Biophys. 70(3), 1913–1921 (2014).Crossref, Medline, CAS, Google Scholar
• 127 Roberts KE, Cushing PR, Boisguerin P, Madden DR, Donald BR. Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity. PLoS Comput. Biol. 8(4), e1002477 (2012).Crossref, Medline, CAS, Google Scholar
• 128 Kilian TM, Kloting N, Bergmann R et al. Rational design of dual peptides targeting ghrelin and Y receptors to regulate food intake and body weight. J. Med. Chem. 58(10), 4180–4193 (2015).• Demonstrates the potential to engineer a single peptide to have multiple bioactivities.Crossref, Medline, CAS, Google Scholar
• 129 Wang CK, Gruber CW, Cemazar M et al. Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis. ACS Chem. Biol. 9(1), 156–163 (2014).Crossref, Medline, CAS, Google Scholar
• 130 Fung HK, Floudas CA, Taylor MS, Zhang L, Morikis D. Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. Biophys. J. 94(2), 584–599 (2008).Crossref, Medline, CAS, Google Scholar
• 131 Bellows-Peterson ML, Fung HK, Floudas CA et al. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J. Med. Chem. 55(9), 4159–4168 (2012).Crossref, Medline, CAS, Google Scholar
• 132 Halai R, Bellows-Peterson ML, Branchett W et al. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. Eur. J. Pharmacol. 745, 176–181 (2014).Crossref, Medline, CAS, Google Scholar
• 133 Gorham RD Jr, Forest DL, Khoury GA et al. New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J. Med. Chem. 58(2), 814–826 (2015).Crossref, Medline, CAS, Google Scholar
• 134 Bellows ML, Taylor MS, Cole PA et al. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys. J. 99(10), 3445–3453 (2010).Crossref, Medline, CAS, Google Scholar
• 135 Wang CK, Northfield SE, Colless B et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl Acad. Sci. USA 111(49), 17504–17509 (2014).• Demonstrates how detailed knowledge about peptide conformation can be used to significantly improve oral bioavailability via small chemical modifications.Crossref, Medline, CAS, Google Scholar
• 136 Jagadish K, Camarero JA. Cyclotides, a promising molecular scaffold for peptide-based therapeutics. Biopolymers 94(5), 611–616 (2010).Crossref, Medline, CAS, Google Scholar
• 137 Poth AG, Chan LY, Craik DJ. Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers 100(5), 480–491 (2013).Crossref, Medline, CAS, Google Scholar
• 138 Wong CT, Rowlands DK, Wong CH et al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew. Chem. Int. Ed. Engl. 51(23), 5620–5624 (2012).Crossref, Medline, CAS, Google Scholar